Video Telehealth Access and Changes in HbA1c Among People With Diabetes

Published:December 07, 2021DOI:


      Video telehealth can offer people convenient, real-time access to clinicians without arranging transportation or time off work. Among people with diabetes, this study examines the association between video telehealth access and changes in HbA1c.


      This longitudinal cohort study (2016–2019) used linear regression with person-level fixed effects, stratified by baseline HbA1c (last value in 2015), to examine the association between video visit access and changes in HbA1c. HbA1c values were categorized into 3 periods of video visit exposure: (1) before any video visit, (2) during video visit transition year (calendar year of the first video visit), and (3) after video visits. The model compared changes in HbA1c values collected before the patient had any video visits with those collected after the transition year. Analyses were conducted in September 2020.


      Among 204,301 people with diabetes, video visit access was associated with a statistically significant reduction of 0.15 (95% CI= −0.19, −0.11) percentage points in HbA1c, with greater reductions among patients with an elevated baseline HbA1c value (−0.22 percentage points, 95% CI= −0.32, −0.11) and with no baseline HbA1c measurement (−0.39 percentage points, 95% CI= −0.71, −0.07).


      Gaining access to video telehealth was associated with reductions in HbA1c among people with diabetes. Video telehealth offers people with chronic conditions a new, convenient way to access health care, is not associated with worsening HbA1c, and may support better disease management, particularly among patients with higher baseline HbA1c.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tilden DR
        • Datye KA
        • Moore DJ
        • French B
        • Jaser SS.
        The rapid transition to telemedicine and its effect on access to care for patients with type 1 diabetes during the COVID-19 pandemic.
        Diabetes Care. 2021; 44: 1447-1450
        • Krapek K
        • King K
        • Warren SS
        • et al.
        Medication adherence and associated hemoglobin A1c in type 2 diabetes.
        Ann Pharmacother. 2004; 38: 1357-1362
        • Lerman I.
        Adherence to treatment: the key for avoiding long-term complications of diabetes.
        Arch Med Res. 2005; 36: 300-306
        • Qaseem A
        • Wilt TJ
        • Kansagara D
        • et al.
        Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians.
        Ann Intern Med. 2018; 168: 569-576
        • AmericanWell
        Telehealth index: 2019 physician survey.
        American Well, Boston, MA2019 (Accessed October 29, 2021.)
        • Burke BL
        • Hall RW
        Telemedicine: pediatric applications.
        Pediatrics. 2015; 136: e293-e308
        • Mehrotra A
        • Jena AB
        • Busch AB
        • Souza J
        • Uscher-Pines L
        • Landon BE
        Utilization of telemedicine among rural Medicare beneficiaries.
        JAMA. 2016; 315: 2015-2016
        • Faruque LI
        • Wiebe N
        • Ehteshami-Afshar A
        • et al.
        Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials.
        CMAJ. 2017; 189: E341-E364
        • Flodgren G
        • Rachas A
        • Farmer AJ
        • Inzitari M
        • Shepperd S.
        Interactive telemedicine: effects on professional practice and health care outcomes.
        Cochrane Database Syst Rev. 2015; 2015CD002098
        • Hamine S
        • Gerth-Guyette E
        • Faulx D
        • Green BB
        • Ginsburg AS.
        Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review.
        J Med Internet Res. 2015; 17: e52
        • Lee SWH
        • Chan CKY
        • Chua SS
        • Chaiyakunapruk N.
        Comparative effectiveness of telemedicine strategies on type 2 diabetes management: a systematic review and network meta-analysis.
        Sci Rep. 2017; 7: 12680
        • Lee SWH
        • Ooi L
        • Lai YK.
        Telemedicine for the management of glycemic control and clinical outcomes of type 1 diabetes mellitus: a systematic review and meta-analysis of randomized controlled studies.
        Front Pharmacol. 2017; 8: 330
        • Zhai YK
        • Zhu WJ
        • Cai YL
        • Sun DX
        • Zhao J.
        Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis.
        Medicine (Baltimore). 2014; 93: e312
        • Stratton IM
        • Adler AI
        • Neil HAW
        • et al.
        Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
        BMJ. 2000; 321: 405-412
        • Domurat ES.
        Diabetes managed care and clinical outcomes: the Harbor City, California Kaiser Permanente diabetes care system.
        Am J Manag CareHarbor. 1999; 5: 1299-1307